Skip to main content

Table 1 Psychiatric adverse effects in DAAs

From: Psychiatric treatment considerations with direct acting antivirals in hepatitis C

   Telaprevir trials    Boceprevir trials  
  ADVANCE [[4]] ILLUMINATE* [[31]] REALIZE [[32]] SPRINT-1 [[33]] SPRINT-2 [[5]] RESPOND-2 [[34]]
Psychiatric side effect       
Fatigue 57% (57%) 68% 55% (40%) 68% (55%) 53% (60%) 54% (50%)
Insomnia 32% (31%) 31% 26% (26%) 28% (38%) 33% (32%) 30% (20%)
Irritability 22% (18%) - 14% (16%) - 22% (24%) 19% (13%)
Depression 18% (22%) - 9% (14%) - 23% (22%) 12% (15%)
Anxiety 10% (12%) - - - - -
  1. % - percent for study arm corresponding to current standard of care for DAA.
  2. (%) – percent for pegylated IFNα and Ribavirin treatment arm.
  3. *ILLUMINATE – did not have pegylated IFNα and Ribavirin treatment arm.